Loïc Vincent
About Loïc Vincent
Loïc Vincent is the Chief Scientific Officer known for his significant contributions to oncology, particularly in presenting preclinical and clinical-stage data on KRAS and p53 mutations at the AACR Annual Meeting 2024.
Loïc Vincent Chief Scientific Officer
Loïc Vincent holds the position of Chief Scientific Officer. In this role, Vincent is responsible for guiding the scientific direction and research initiatives of the organization. His work primarily focuses on advancing oncology research and developing therapeutic strategies targeting key oncogenic drivers. As Chief Scientific Officer, Vincent plays a crucial part in overseeing the preclinical and clinical research programs within the company.
Loïc Vincent Presentation at AACR Annual Meeting 2024
At the American Association for Cancer Research (AACR) Annual Meeting 2024, Loïc Vincent presented significant preclinical data from oncogenic driver programs targeting KRAS G12D and p53 R175H. These presentations are critical for sharing advancements in cancer research with the broader scientific community. By presenting these preclinical findings, Vincent contributes to the ongoing discourse in oncology research and highlights the progress made by his team in developing potential cancer therapies.
Loïc Vincent Phase 1 Clinical-Stage Posters at AACR 2024
Loïc Vincent presented two trial-in-progress posters for Phase 1 clinical-stage programs targeting KRAS G12V at the AACR Annual Meeting 2024. These posters detail the ongoing clinical trials and offer insights into the early-stage results and methodologies. By sharing this information, Vincent provides valuable data to the scientific community and underscores the potential of these clinical-stage programs to contribute to future cancer treatment strategies.